Journal article
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
Abstract
Background: Mitogen-activated protein kinase kinase (MEK) is activated by mutated KRAS in >90% of pancreatic ductal adenocarcinoma (PDAC). MEK and focal adhesion kinase (FAK) are frequently co-activated in PDAC providing a rationale for combining trametinib, an oral allosteric MEK1/2 inhibitor, with GSK2256098, an oral FAK inhibitor.
Methods: Advanced PDAC patients whose disease progressed after first line palliative chemotherapy were treated …
Authors
Aung KL; McWhirter E; Welch S; Wang L; Lovell S; Stayner L-A; Ali S; Malpage A; Makepeace B; Ramachandran M
Journal
Journal of Gastrointestinal Oncology, Vol. 0, No. 0, pp. 0–0
Publisher
AME Publishing Company
Publication Date
December 2022
DOI
10.21037/jgo-22-86
ISSN
2078-6891